S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Sponsor: National Cancer Institute (NCI)
Listed as NCT00874211, this observational or N/A phase trial focuses on Breast Cancer and Lung Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 19 times since 2008, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Study Description(click to expand)OBJECTIVES:
Primary
* To prospectively access the cumulative incidence of osteonecrosis of the jaw (ONJ) at 3 years in cancer patients with bone metastasis receiving zoledronic acid treatment.
Secondary
* To describe the clinical presentation and natural history of ONJ.
* To identify potential risk factors for the development of ONJ.
* To estimate the cumulative incidence of ONJ at 3 years for different tumor types (i.e., breast cancer, multiple myeloma, prostate cancer, lung cancer, and other cancers).
* To better define the patient-related outcomes of ONJ.
OUTLINE: This is a multicenter study.
Patients undergo dental assessments at baseline and every 3-6 months for 3 years.
OBJECTIVES:
Primary
* To prospectively access the cumulative incidence of osteonecrosis of the jaw (ONJ) at 3 years in cancer patients with bone metastasis receiving zoledronic acid treatment.
Secondary
* To describe the clinical presentation and natural history of ONJ. * To identify potential risk factors for the development of ONJ. * To estimate the cumulative incidence of ONJ at 3 years for different tumor types (i.e., breast cancer, multiple myeloma, prostate cancer, lung cancer, and other cancers). * To better define the patient-related outcomes of ONJ.
OUTLINE: This is a multicenter study.
Patients undergo dental assessments at baseline and every 3-6 months for 3 years.
Status Flow
Change History
19 versions recorded-
Jan 2026 — Present [monthly]
Completed
-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
May 2023 — Jul 2024 [monthly]
Completed
▶ Show 14 earlier versions
-
Dec 2021 — May 2023 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Aug 2019 — Nov 2020 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jun 2019 — Aug 2019 [monthly]
Active Not Recruiting
-
Apr 2019 — Jun 2019 [monthly]
Active Not Recruiting
-
Nov 2018 — Apr 2019 [monthly]
Active Not Recruiting
-
Jul 2018 — Nov 2018 [monthly]
Active Not Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — May 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Dec 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Novartis
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .